CDM Insights

CDM Insights is a post-processing image analysis software designed to assist healthcare practitioners in evaluating MR brain images of adults over 45 by performing automated segmentation and quantitative analysis of brain structures and white matter hyperintensities. Its scientific methodology involves comparing these quantified structures against normative data from a healthy population, ensuring reliable and reproducible results for clinical assessment.

Oxford Brain Diagnostics Ltd's device, CDM Insights, a post-processing image analysis software, has been determined to be substantially equivalent to a legally marketed device. This software is designed to assist trained healthcare practitioners in viewing, analyzing, and evaluating MR brain images of adults over 45 years of age. Its functionalities include automated segmentation and quantitative analysis of individual brain structures and white matter hyperintensities, quantitative comparison of these structures with normative data from a healthy population, and presentation of results with numerical values and visualizations.The device is classified as a Class II medical image management and processing system and is subject to various general and special controls, including requirements for annual registration, good manufacturing practice, and labeling. Non-clinical tests were conducted to confirm the functionality and performance of CDM Insights, demonstrating its safety and effectiveness. These tests included software validation, bench testing, and extensive performance assessments for accuracy, repeatability, and reproducibility, all of which successfully met pre-specified acceptance criteria.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does CDM Insights' automated segmentation and quantitative analysis compare in diagnostic accuracy for specific neurodegenerative conditions versus current gold-standard methods?; What are the specific characteristics and sources of the normative data sets used by CDM Insights, and how are potential biases or variability accounted for?; Beyond the specified age group, has the performance and utility of CDM Insights been evaluated in younger populations or for conditions not primarily associated with aging?; What is the clinical workflow integration for CDM Insights, and what training or certification is required for healthcare practitioners to effectively use and interpret its results?; Are there any known limitations or specific MRI acquisition protocols that could impact the accuracy or reliability of the quantitative results generated by CDM Insights?